Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 180

1.

A Stent for Every Stone? Prestenting Habits and Outcomes from a German Multicenter Prospective Study on the Benchmarks of Ureteroroscopic Stone Treatment (BUSTER).

Werthemann P, Weikert S, Enzmann T, Schostak M, Lebentrau S.

Urol Int. 2020 Jan 24:1-6. doi: 10.1159/000504682. [Epub ahead of print]

PMID:
31982881
2.

MRI targeted single fraction HDR Brachytherapy for localized Prostate Carcinoma: a feasibility study of focal radiation therapy (ProFocAL).

Fischbach F, Hass P, Schindele D, Genseke P, Geisendorf L, Stehning C, Schostak M, Brunner T, Pech M, Fischbach K.

Eur Radiol. 2019 Dec 11. doi: 10.1007/s00330-019-06505-0. [Epub ahead of print]

PMID:
31828412
3.

[Changes in the treatment of metastatic prostate cancer-new data and open questions].

Albers P, Bögemann M, Machtens S, Merseburger AS, Schostak M, Steuber T, Wülfing C, De Santis M.

Urologe A. 2019 Nov 28. doi: 10.1007/s00120-019-01072-0. [Epub ahead of print] German.

PMID:
31781782
4.

A Phase 4 Study of Everolimus to Evaluate Efficacy and Safety in Patients with Metastatic Renal-Cell Carcinoma after Failure of First-Line Sunitinib or Pazopanib (SUNPAZ).

Schostak M, de Geeter P, Decker T, Resch A, Quiering C, Schmitz S.

Urol Int. 2019 Nov 14:1-6. doi: 10.1159/000503870. [Epub ahead of print]

PMID:
31726458
5.

Ureteroenteric strictures: a single center experience comparing Bricker versus Wallace ureteroileal anastomosis in patients after urinary diversion for bladder cancer.

Christoph F, Herrmann F, Werthemann P, Janik T, Schostak M, Klopf C, Weikert S.

BMC Urol. 2019 Oct 24;19(1):100. doi: 10.1186/s12894-019-0529-6.

6.

Prospective multicentre study using high intensity focused ultrasound (HIFU) for the focal treatment of prostate cancer: Safety outcomes and complications.

Schmid FA, Schindele D, Mortezavi A, Spitznagel T, Sulser T, Schostak M, Eberli D.

Urol Oncol. 2019 Oct 15. pii: S1078-1439(19)30352-7. doi: 10.1016/j.urolonc.2019.09.001. [Epub ahead of print]

PMID:
31628038
7.

Rogaratinib in patients with advanced cancers selected by FGFR mRNA expression: a phase 1 dose-escalation and dose-expansion study.

Schuler M, Cho BC, Sayehli CM, Navarro A, Soo RA, Richly H, Cassier PA, Tai D, Penel N, Nogova L, Park SH, Schostak M, Gajate P, Cathomas R, Rajagopalan P, Grevel J, Bender S, Boix O, Nogai H, Ocker M, Ellinghaus P, Joerger M.

Lancet Oncol. 2019 Oct;20(10):1454-1466. doi: 10.1016/S1470-2045(19)30412-7. Epub 2019 Aug 9.

PMID:
31405822
8.

Awareness and perception of multidrug-resistant organisms and antimicrobial therapy among internists vs. surgeons of different specialties: Results from the German MR2 Survey.

Spachmann PJ, May M, Vetterlein MW, Fritsche HM, Steffen S, Schostak M, Wagenlehner FM, Burger M, Weylandt KH, Salzberger B, Brookman-May SD, Gilfrich C; MR2 study group.

Caspian J Intern Med. 2019 Spring;10(2):132-141. doi: 10.22088/cjim.10.2.132.

9.

How well do software assistants for minimally invasive partial nephrectomy meet surgeon information needs? A cognitive task analysis and literature review study.

Joeres F, Schindele D, Luz M, Blaschke S, Russwinkel N, Schostak M, Hansen C.

PLoS One. 2019 Jul 18;14(7):e0219920. doi: 10.1371/journal.pone.0219920. eCollection 2019.

10.

Erratum zu: Therapiesituation beim metastasierten kastrationsnaiven Prostatakarzinom (mCNPC) und die Auswirkungen im klinischen Alltag.

Wülfing C, Bögemann M, Goebell PJ, Hammerer P, Machtens S, Pfister D, Schwentner C, Steuber T, von Amsberg G, Schostak M.

Urologe A. 2019 Aug;58(8):924. doi: 10.1007/s00120-019-0985-3. German. No abstract available.

PMID:
31236656
11.

[The Onkonet database: taking stock of an Internet-based, multi-centre database on surgical prostate cancer treatment].

Pohle M, Magheli A, Diederichs W, Ecke T, Fischer T, Kempkensteffen C, Knispel H, Lehsnau M, Miller K, Pretzer J, Schostak M, Winter A, Zacharias M, Hinz S.

Aktuelle Urol. 2019 Jun 13. doi: 10.1055/a-0919-3993. [Epub ahead of print] German.

PMID:
31195415
12.

[Treatment situation in metastastic Castration Naive Prostate Cancer (mCRPC) and the implications on clinical routine].

Wülfing C, Bögemann M, Goebell PJ, Hammerer P, Machtens S, Pfister D, Schwentner C, Steuber T, von Amsberg G, Schostak M.

Urologe A. 2019 Sep;58(9):1066-1072. doi: 10.1007/s00120-019-0925-2. Review. German. Erratum in: Urologe A. 2019 Aug;58(8):924.

PMID:
31041460
13.

[Focal therapy in prostate cancer : Five-year outcome].

Schindele D, Schostak M.

Urologe A. 2019 May;58(5):562-563. doi: 10.1007/s00120-019-0902-9. German. No abstract available.

PMID:
30953091
14.

Small renal carcinoma: the "when" and "how" of operation, active surveillance, and ablation.

Wendler JJ, Liehr BU, Damm R, Powerski M, Brunner T, Schostak M, Pech M.

Pol J Radiol. 2018 Dec 22;83:e561-e568. doi: 10.5114/pjr.2018.81282. eCollection 2018. Review.

15.

[Focal therapy for prostate cancer].

Schostak M.

Urologe A. 2019 May;58(5):518-523. doi: 10.1007/s00120-019-0862-0. Review. German.

PMID:
30734839
16.

The importance of sexuality, changes in erectile functioning and its association with self-esteem in men with localized prostate cancer: data from an observational study.

Hilger C, Schostak M, Neubauer S, Magheli A, Fydrich T, Burkert S, Kendel F.

BMC Urol. 2019 Jan 21;19(1):9. doi: 10.1186/s12894-019-0436-x.

17.

Guidelines for patients with acute uncomplicated cystitis may not be a paper tiger: a call for its implementation in clinical routine.

May M, Schostak M, Lebentrau S; MR2- study group.

Int Urogynecol J. 2019 Feb;30(2):335-336. doi: 10.1007/s00192-018-3851-8. Epub 2018 Dec 18. No abstract available.

PMID:
30564871
18.

Risk Factors for Ureteral Damage in Ureteroscopic stone Treatment: Results of the German Prospective Multicentre Benchmarks of Ureterorenoscopic Stone Treatment-Results in Terms of Complications, Quality of Life, and Stone-Free Rates Project.

Lebentrau S, Müller PF, Miernik A, Schönthaler M, Gilfrich C, Peter J, Schostak M, May M; BUSTER study group.

Urol Int. 2019;102(2):187-193. doi: 10.1159/000495072. Epub 2018 Nov 27.

PMID:
30481771
19.

Hospital volume in ureterorenoscopic stone treatment: 99 operations per year could increase the chance of a better outcome-results of the German prospective multicentre BUSTER project.

Lebentrau S, Enzmann T, Lehsnau M, Christoph F, Schostak M, May M; BUSTER study group.

World J Urol. 2019 Apr;37(4):743-749. doi: 10.1007/s00345-018-2431-3. Epub 2018 Aug 9.

PMID:
30094717
20.

Prostate cancer treatment by the latest focal HIFU device with MRI/TRUS-fusion control biopsies: A prospective evaluation.

von Hardenberg J, Westhoff N, Baumunk D, Hausmann D, Martini T, Marx A, Porubsky S, Schostak M, Michel MS, Ritter M.

Urol Oncol. 2018 Sep;36(9):401.e1-401.e9. doi: 10.1016/j.urolonc.2018.05.022. Epub 2018 Aug 6.

PMID:
30093211
21.

Impact of surgeon's experience on outcome parameters following ureterorenoscopic stone removal.

Wolff I, Lebentrau S, Miernik A, Ecke T, Gilfrich C, Hoschke B, Schostak M, May M; BUSTER study group.

Urolithiasis. 2019 Oct;47(5):473-479. doi: 10.1007/s00240-018-1073-7. Epub 2018 Jul 4.

PMID:
29974193
22.

[Differences between the inpatient complication rate after ureterorenoscopy and the 30-day outcome reported by the patient - results of the German prospective BUSTER study].

Wolff I, May M, Hoschke B, Gilfrich C, Peter J, Ecke T, Schostak M, Lebentrau S.

Aktuelle Urol. 2019 Feb;50(1):63-70. doi: 10.1055/a-0621-8705. Epub 2018 Jun 12. Review. German.

PMID:
29895078
23.

[Advanced Prostate Cancer Consensus Conference 2017 : Discussion of the recommendations for diagnosis and treatment of metastatic prostate cancer by a German panel of experts].

Schostak M, König F, Bögemann M, Goebell P, Hammerer P, Machtens S, Schwentner C, Thomas C, von Amsberg G, von Rundstedt FC, Heidenreich A.

Urologe A. 2018 Jul;57(7):813-820. doi: 10.1007/s00120-018-0680-9. German.

PMID:
29808368
24.

[Small renal cell carcinoma-active surveillance and ablation].

Wendler JJ, Damm R, Liehr UB, Brunner T, Pech M, Schostak M.

Urologe A. 2018 Jun;57(6):731-743. doi: 10.1007/s00120-018-0677-4. German.

PMID:
29796702
25.

Age does not matter: the relevance of immediate instillation therapy with Mitomycin C in non-muscle invasive bladder cancer.

Christoph F, Schostak M.

Transl Androl Urol. 2018 Apr;7(2):289-291. doi: 10.21037/tau.2018.03.11. No abstract available.

26.

Crosstalk between Akt signaling and cold shock proteins in mediating invasive cell phenotypes.

Hohlfeld R, Brandt S, Bernhardt A, Gorny X, Schindele D, Jandrig B, Schostak M, Isermann B, Lindquist JA, Mertens PR.

Oncotarget. 2018 Apr 10;9(27):19039-19049. doi: 10.18632/oncotarget.24886. eCollection 2018 Apr 10.

27.

Re: Letter to the editor.

Lebentrau S, Gilfrich C, Vetterlein MW, Schumacher H, Spachmann PJ, Brookman-May SD, Fritsche HM, Schostak M, Wagenlehner FM, Burger M, May M.

Int Urol Nephrol. 2018 May;50(5):875. doi: 10.1007/s11255-018-1808-y. Epub 2018 Feb 13. No abstract available.

PMID:
29441478
28.

Feasibility study of MR-guided transgluteal targeted in-bore biopsy for suspicious lesions of the prostate at 3 Tesla using a freehand approach.

Fischbach F, Wien L, Krueger S, Schnackenburg B, Baumunk D, Friebe B, Schostak M, Ricke J, Fischbach K.

Eur Radiol. 2018 Jun;28(6):2690-2699. doi: 10.1007/s00330-017-5187-z. Epub 2018 Jan 17.

PMID:
29344699
29.

[Interrater reliability and clinical impact of the Post-Ureteroscopic Lesion Scale (PULS) grading system for ureteral lesions after ureteroscopy : Results of the German prospective multicenter BUSTER project].

May M, Schönthaler M, Gilfrich C, Wolff I, Peter J, Miernik A, Fritsche HM, Burger M, Schostak M, Lebentrau S; BUSTER-Arbeitsgruppe.

Urologe A. 2018 Feb;57(2):172-180. doi: 10.1007/s00120-017-0565-3. German.

PMID:
29322235
30.

Initial Assessment of the Efficacy of Irreversible Electroporation in the Focal Treatment of Localized Renal Cell Carcinoma With Delayed-interval Kidney Tumor Resection (Irreversible Electroporation of Kidney Tumors Before Partial Nephrectomy [IRENE] Trial-An Ablate-and-Resect Pilot Study).

Wendler JJ, Pech M, Fischbach F, Jürgens J, Friebe B, Baumunk D, Porsch M, Blaschke S, Schindele D, Siedentopf S, Ricke J, Schostak M, Köllermann J, Liehr UB.

Urology. 2018 Apr;114:224-232. doi: 10.1016/j.urology.2017.12.016. Epub 2018 Jan 2.

PMID:
29305201
31.

RANKL/RANK/OPG cytokine receptor system: mRNA expression pattern in BPH, primary and metastatic prostate cancer disease.

Christoph F, König F, Lebentrau S, Jandrig B, Krause H, Strenziok R, Schostak M.

World J Urol. 2018 Feb;36(2):187-192. doi: 10.1007/s00345-017-2145-y. Epub 2017 Dec 4.

PMID:
29204705
32.

PBRM1 and VHL expression correlate in human clear cell renal cell carcinoma with differential association with patient's overall survival.

Högner A, Krause H, Jandrig B, Kasim M, Fuller TF, Schostak M, Erbersdobler A, Patzak A, Kilic E.

Urol Oncol. 2018 Mar;36(3):94.e1-94.e14. doi: 10.1016/j.urolonc.2017.10.027. Epub 2017 Nov 21.

PMID:
29169846
33.

Prospective Multicenter Phase II Study on Focal Therapy (Hemiablation) of the Prostate with High Intensity Focused Ultrasound.

Ganzer R, Hadaschik B, Pahernik S, Koch D, Baumunk D, Kuru T, Heidenreich A, Stolzenburg JU, Schostak M, Blana A.

J Urol. 2018 Apr;199(4):983-989. doi: 10.1016/j.juro.2017.10.033. Epub 2017 Oct 26.

PMID:
29107031
34.

Non-muscle invasive bladder cancer: Are epicrises the 'Bermuda Triangle' of information transfer?

Lebentrau S, May M, Wick AK, Roiner M, Mathew M, Gilfrich C, Schostak M.

Cent European J Urol. 2017;70(3):245-251. doi: 10.5173/ceju.2017.1447. Epub 2017 Jul 14.

36.

[The recommendations of the S2k guideline for the diagnosis, therapy and metaphylaxis of urolithiasis provide a safe course of action for ureterorenoscopic stone treatment - results of the BUSTER study].

Lebentrau S, May M, Ziegler H, Werthemann P, Enzmann T, Schostak M, Porsch M; BUSTER-Studiengruppe.

Aktuelle Urol. 2018 Apr;49(2):164-170. doi: 10.1055/s-0043-116859. Epub 2017 Oct 12. German.

PMID:
29025177
37.

Upper-Urinary-Tract Effects After Irreversible Electroporation (IRE) of Human Localised Renal-Cell Carcinoma (RCC) in the IRENE Pilot Phase 2a Ablate-and-Resect Study.

Wendler JJ, Pech M, Köllermann J, Friebe B, Siedentopf S, Blaschke S, Schindele D, Porsch M, Baumunk D, Jürgens J, Fischbach F, Ricke J, Schostak M, Böhm M, Liehr UB.

Cardiovasc Intervent Radiol. 2018 Mar;41(3):466-476. doi: 10.1007/s00270-017-1795-x. Epub 2017 Sep 19.

PMID:
28929209
38.

[Thermochemotherapy with Mitomycin C: an update on alternative treatment strategies in non-muscleinvasive bladder cancer].

Christoph F, König F, Lebentrau S, Blaschke S, Liehr UB, Schostak M.

Aktuelle Urol. 2018 Apr;49(2):157-163. doi: 10.1055/s-0043-109414. Epub 2017 Sep 19. Review. German.

PMID:
28926864
39.

Virtual and Augmented Reality Systems for Renal Interventions: A Systematic Review.

Detmer FJ, Hettig J, Schindele D, Schostak M, Hansen C.

IEEE Rev Biomed Eng. 2017;10:78-94. doi: 10.1109/RBME.2017.2749527. Epub 2017 Sep 6. Review.

PMID:
28885161
40.

[Focal therapy of prostate cancer].

Ganzer R, Franiel T, Köllermann J, Kuru T, Baumunk D, Blana A, Hadaschik B, von Hardenberg J, Henkel T, Köhrmann KU, Liehr UB, Machtens S, Roosen A, Salomon G, Schlemmer HP, Sentker L, Wendler J, Witzsch U, Schostak M.

Urologe A. 2017 Oct;56(10):1335-1346. doi: 10.1007/s00120-017-0488-z. German.

PMID:
28856386
41.

[Non-PSA-expressing, solid, and growing mass of the prostate].

Christoph F, Ebrahimsade S, Schostak M.

Urologe A. 2017 Oct;56(10):1320-1322. doi: 10.1007/s00120-017-0465-6. German. No abstract available.

PMID:
28730287
42.

[Metastatic prostate cancer : Update: position paper for the use of chemotherapy].

Ohlmann CH, Goebell PJ, Grimm MO, Klier J, König F, Machtens S, Schostak M, Schrader AJ, Albers P.

Urologe A. 2017 Dec;56(12):1597-1602. doi: 10.1007/s00120-017-0459-4. Review. German.

PMID:
28695241
43.

[Prostate gland - what would urologists like to know from radiologists?]

Liehr UB, Baumunk D, Blaschke S, Fischbach F, Friebe B, König F, Lemke A, Mittelstädt P, Pech M, Porsch M, Ricke J, Schindele D, Siedentopf S, Wendler JJ, Schostak M.

Radiologe. 2017 Aug;57(8):608-614. doi: 10.1007/s00117-017-0273-4. Review. German.

PMID:
28660295
44.

[Do General Surgeons Feel Adequately Prepared for the Complex Questions Associated with the Handling of Multi-Resistant Pathogens? - Results of the MR2 Survey].

May M, Spachmann PJ, Lebentrau S, Schumacher H, Gilfrich C, Fritsche HM, Vetterlein M, Brookman-May S, Schostak M, Wagenlehner FM, Burger M, Novotny A, Obermaier R.

Zentralbl Chir. 2017 Jun;142(3):297-305. doi: 10.1055/s-0042-120546. Epub 2017 Jun 22. German.

PMID:
28641352
45.

[What is the perception of the 10-point plan of the German Federal Ministry of Health against multidrug-resistant pathogens and measures of antibiotic stewardship? : An interdisciplinary analysis among German clinicians and development of a decision tool for urologists].

May M, Vetterlein MW, Wagenlehner FM, Brookman-May SD, Gilfrich C, Fritsche HM, Spachmann PJ, Burger M, Schostak M, Lebentrau S; MR2-Studiengruppe.

Urologe A. 2017 Oct;56(10):1302-1310. doi: 10.1007/s00120-017-0425-1. German.

PMID:
28593351
46.

Impact of the medical specialty on knowledge regarding multidrug-resistant organisms and strategies toward antimicrobial stewardship.

Lebentrau S, Gilfrich C, Vetterlein MW, Schumacher H, Spachmann PJ, Brookman-May SD, Fritsche HM, Schostak M, Wagenlehner FM, Burger M, May M; MR2 study group.

Int Urol Nephrol. 2017 Aug;49(8):1311-1318. doi: 10.1007/s11255-017-1603-1. Epub 2017 Apr 21.

PMID:
28432607
47.

Radioablation of adrenal gland malignomas with interstitial high-dose-rate brachytherapy : Efficacy and outcome.

Mohnike K, Neumann K, Hass P, Seidensticker M, Seidensticker R, Pech M, Klose S, Streitparth T, Garlipp B, Benckert C, Wendler JJ, Liehr UB, Schostak M, Göppner D, Gademann G, Ricke J.

Strahlenther Onkol. 2017 Aug;193(8):612-619. doi: 10.1007/s00066-017-1120-2. Epub 2017 Mar 24.

PMID:
28341865
48.

[When is cytoreductive nephrectomy not beneficial for patients with metastatic renal cell carcinoma?]

Schostak M.

Urologe A. 2017 May;56(5):610-616. doi: 10.1007/s00120-017-0363-y. Review. German.

PMID:
28314968
49.

Inability of shear-wave elastography to distinguish malignant from benign prostate tissue - a comparison of biopsy, whole-mount sectioning and shear-wave elastography.

Porsch M, Görner C, Wendler JJ, Liehr UB, Lux A, Siedentopf S, Schostak M, Pech M.

J Ultrason. 2016 Dec;16(67):348-358. doi: 10.15557/JoU.2016.0035. Epub 2016 Dec 30.

50.

Autoantibodies Directed Against the Endothelin A Receptor in Patients With Benign Prostatic Hyperplasia.

Wallukat G, Jandrig B, Kunze R, Wendler JJ, Müller J, Schostak M, Schimke I.

Prostate. 2017 Apr;77(5):458-465. doi: 10.1002/pros.23284. Epub 2016 Nov 24.

PMID:
27882567

Supplemental Content

Loading ...
Support Center